Zonisamide

Epilepsy

Azurity PharmaceuticalsSmall moleculePhase 4 / ApprovedActive

BB

69/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 67/ 100
Competitive Position: 73/ 100

Competitive context

76 Active assets in the Epilepsy cohort.

Asset / Sponsor	Phase	Rating
Topamax SK Life Science, Inc.	Phase 4	BBB
Keppra Beijing Tiantan Hospital	Phase 4	BBB
Topamax Université de Sherbrooke	Phase 4	BBB
Carbamazepine Assistance Publique - Hôpitaux de Paris	Phase 4	BBB
LAMOTRIGINE Assiut University	Phase 4	BBB

View all 50 →

Same molecule, other indications

Zonisamide is also rated in:

focal epilepsyDormant

BBB

Indicative ·

74 / 100

migraine disorderDormant

B

Indicative ·

63 / 100

epilepsyDormant

B

Indicative ·

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.